Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP)

Status Completed

Clinical Trial Summary

Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and the risk of severe bleeding complications. The two recently introduced TPO-RA drugs, namely, eltrombopag and romiplostim, have shown efficacious sustained response with continuous administration. Both drugs are indicated for the treatment of thrombocytopia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. While these trials address important clinical questions they were not intended to evaluate what happens in the real-world settings with actual patient living daily lives. The purpose of this health outcomes study is to understand how the two TPO receptor agonists (TPO-RA) currently available in the US are being used in clinical practice and how their use impacts chronic ITP patients' daily lives. The study hypothesis is that patients who switched to eltrombopag report a better health-related quality of life than those who switched to romiplostim. This study utilized a hybrid design of retrospective chart review study and cross-sectional patient survey. A customized Patient Case Report Form (CRF) will be used to retrospectively collect clinical data from patient medical charts where the primary cohorts consist of patients who have switched from other ITP medication to eltrombopag or romiplostim. A cross-sectional survey will be employed to collect patient reported outcomes (PRO) data, including health-related quality of life and treatment satisfaction, using a compository questionnaire. Analyses of cross-sectional survey data and retrospective medical chart review data in patients who switch to either eltrombopag or romiplostim from their prior primary therapy will be conducted.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Immune Thrombocytopenic Purpura
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic

Clinical Trial Details

NCT number	NCT01439321
Study type	Observational
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	N/A
Start date	November 2010
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01255332` - Helicobacter Pylori Immune Thrombocytopenic Purpura	Phase 2
Completed	`NCT02077192` - Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Phase 3
Completed	`NCT01621204` - A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients	Phase 3
Completed	`NCT01719692` - Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia	N/A
Completed	`NCT01730352` - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients	Phase 2/Phase 3
Completed	`NCT01713855` - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura	N/A
Not yet recruiting	`NCT05093257` - Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
Completed	`NCT01390649` - A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)	Phase 4
Completed	`NCT01672151` - Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia	N/A
Completed	`NCT00774202` - Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP	Phase 2/Phase 3
Completed	`NCT02273960` - Study to Evaluate Safety and Efficacy in Adult Subjects With ITP	Phase 1/Phase 2
Not yet recruiting	`NCT05585944` - " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "	N/A
Recruiting	`NCT03177629` - H. Pylori Eradication for Moderate ITP	Phase 3
Not yet recruiting	`NCT05835050` - Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital	N/A
Active, not recruiting	`NCT03395210` - A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)	Phase 2
Completed	`NCT00621894` - Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation	Phase 2
Completed	`NCT01652599` - Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT	Phase 2
Completed	`NCT00426270` - Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults	Phase 3
Completed	`NCT02085993` - Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training	N/A
Completed	`NCT00718692` - Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms